Filing Flows › Charles River Laboratories International (CRL) › Q3 2026 › vs Q2 2026
Charles River Laboratories International (CRL) Q3 2026 vs Q2 2026 (quarter over quarter)
Charles River Laboratories International's revenue fell $21.3M (-2%) from $1.0B in Q2 2026 to $983M in Q3 2026. The biggest changes: DSA −$10.2M (-2%); Manufacturing −$9.2M (-5%); RMS −$1.9M (-0.9%). Operating margin 20.6% against 11.9% (+8.7 pts).
Charles River Laboratories International, Q3 2026: revenue $983M (-2% year over year), operating margin 20.6%, net earnings $333M, operating cash flow $254M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 20.6% | 11.9% | +8.7 pts |
| Net margin | 33.9% | -0.1% | +34.0 pts |
| Free cash flow margin | 21.1% | 14.8% | +6.3 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| DSA | $596M | $607M | −$10.2M | -2% |
| RMS | $208M | $209M | −$1.9M | -0.9% |
| Manufacturing | $179M | $188M | −$9.2M | -5% |
| Revenue | $983M | $1.0B | −$21.3M | -2% |
| Operating profit | $203M | $120M | $82.8M | +69% |
| Costs & expenses | $780M | $884M | −$104M | -12% |
| Pre-tax earnings | $171M | $53.2M | $117M | +221% |
| Other expense, net | $32.0M | $66.7M | −$34.7M | -52% |
| SG&A | $141M | $229M | −$88.3M | -39% |
| Other operating costs | $640M | $655M | −$15.8M | -2% |
| Income tax benefit | $164M | −$53.9M | $218M | — |
| Net earnings | $333M | −$1.5M | $335M | — |
| Minority interests | $1.4M | $722K | $655K | +91% |
| Depreciation & amortization | $72.3M | $67.3M | $5.0M | +7% |
| Share-based compensation | $20.8M | $19.8M | $986K | +5% |
| Working capital & other | $172M | −$94.1M | $266M | — |
| Operating cash flow | $254M | $180M | $74.4M | +41% |
| Free cash flow (OCF − capex) | $207M | $149M | $58.7M | +39% |
| Capital expenditures | $46.8M | $31.1M | $15.7M | +50% |
Questions
How much did Charles River Laboratories International's revenue grow quarter over quarter in Q3 2026?
Charles River Laboratories International's revenue fell $21.3M (-2%) from $1.0B in Q2 2026 to $983M in Q3 2026.
What drove Charles River Laboratories International's revenue change in Q3 2026?
DSA −$10.2M (-2%); Manufacturing −$9.2M (-5%); RMS −$1.9M (-0.9%).